Ipamorelin lab monitoring
Which blood work to run before, during and after an ipamorelin cycle, and what the research can and can't tell you about the results. Ipamorelin raises growth hormone pulses, but no published human study has measured what it does to IGF-1, and in rats it didn't change IGF-1 at all (PMID 10373343). So this panel is a safety baseline. It doesn't prove the peptide is working.
When to test
1. Baseline (before you start)
| Marker | Why test it | Standard range |
|---|---|---|
| IGF-1 Insulin-like growth factor 1 | Your reference point. No human study has measured ipamorelin's effect on IGF-1, so there is no expected change to compare against (PMID 10373343). | Depends on age and sex. Labcorp adult examples: ages 21-25, men 109-353 and women 101-347; ages 41-45, men 84-270 and women 74-239; ages 56-60, men 68-247 and women 60-207 ng/mL Source: Labcorp test 010363 |
| Fasting glucose Fasting plasma glucose | Growth hormone works against insulin (PMID 29025199), so you want to know your starting glucose before you push the GH axis. Fast for at least 8 hours before the draw. | Normal under 100; prediabetes 100-125; diabetes 126 or higher mg/dL Source: American Diabetes Association |
| HbA1c Hemoglobin A1c | A one-off screen for existing blood-sugar problems. It reflects roughly the last 3 months, so it is too slow to show change within an 8-12 week cycle. Fasting glucose is the marker to repeat. | Normal under 5.7%; prediabetes 5.7-6.4%; diabetes 6.5% or higher Source: American Diabetes Association |
| CBC Complete blood count | A standard safety baseline before any injectable peptide, so you have your own reference point if you feel unwell during the cycle. | WBC 4.0-10 k/mcL; hemoglobin 13-17 g/dL men, 11.5-15.5 g/dL women; platelets 150-400 k/mcL Source: Cleveland Clinic |
2. Mid-cycle (week 4)
tracking only, no human benchmark for IGF-1
| Marker | Why test it |
|---|---|
| IGF-1 Insulin-like growth factor 1 | Tracks against your baseline, same lab. Draw it before that day's dose. There is no human benchmark for how much it should move. |
| Fasting glucose Fasting plasma glucose | The timely check on GH's effect on blood sugar. Same fasting conditions as baseline. |
3. Post-cycle (2-4 weeks after your last dose)
| Marker | Why test it |
|---|---|
| IGF-1 Insulin-like growth factor 1 | Compare with baseline and week 4. |
| Fasting glucose Fasting plasma glucose | Confirms glucose is back where it started. |
Ranges differ between labs. IGF-1 ranges also depend on age, sex and the assay the lab uses, so run every IGF-1 draw at the same lab and read it against the age band printed on your own report. Glucose and HbA1c cut-offs are the American Diabetes Association's diagnostic thresholds. CBC ranges come from Cleveland Clinic.
What to expect
-
IGF-1: no human IGF-1 benchmark (baseline, week 4, post-cycle)
No published human study has reported IGF-1 on ipamorelin. In rats given ipamorelin for 15 days, bones grew but "the treatment did not affect total IGF-I levels" (PMID 10373343). A rise, no change or a fall can't be compared with anything.
If it doesn't: IGF-1 can't vouch for your vial. A flat result doesn't prove the vial is fake, and a rise doesn't prove it's ipamorelin. Check the certificate of analysis for your batch.
-
Fasting glucose: may drift up; should stay in range (baseline, week 4, post-cycle)
Growth hormone raises blood sugar by working against insulin (PMID 29025199). No human study has reported glucose on ipamorelin, so this is class evidence, not ipamorelin data.
If it doesn't: A move from normal into the prediabetes range (100 or higher) is a reason to stop and talk to a clinician, whatever the source of the vial.
Your labs can't check your vial
Your labs can't check your vial, and for ipamorelin IGF-1 can't even hint, because there is no human benchmark. Danish customs seizures analysed by forensic chemists contained glycine-modified analogs of ipamorelin and modified GRF 1-29, not the compounds themselves (PMID 30136411), and a German survey of black-market products found peptide hormones among the doping agents seized (PMID 25168622). FDA says compounded ipamorelin acetate "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities" and "also contains unnatural amino acids, which add to the complexity of peptide characterization." Identity and purity get checked on the product's certificate of analysis, against the testing lab's own record.
What the research doesn't show
- No published human study has measured IGF-1, glucose or HbA1c on ipamorelin. The IGF-1 data is from rats (PMID 10373343).
- The largest human trial gave ipamorelin IV after bowel surgery, 0.03 mg/kg twice daily for up to 7 days, in 114 patients (PMID 25331030). That is a different route, population and purpose from self-administered subcutaneous use.
- Ipamorelin's selectivity (GH release without ACTH or cortisol) was shown in animals, not people (PMID 9849822).
- Prolactin and cortisol are not on this panel. Reviews list rises in both as class effects of GH-axis peptides (PMID 42395176), but ipamorelin did not raise either in animal studies (PMID 9849822), and CJC-1295 did not raise them in humans (PMID 16352683). Unexplained breast tenderness or nipple discharge is a reason to see a clinician.
- Banned in sport: the 2026 WADA Prohibited List names ipamorelin as an example of a growth hormone secretagogue under S2, prohibited at all times.
Sources
- Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res 1999. PMID 10373343
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822
- Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014. PMID 25331030
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006. PMID 16352683
- Labcorp test 010363: Insulin-like growth factor 1 (IGF-1), age- and sex-specific reference ranges
- American Diabetes Association: Diagnosis (A1C and fasting plasma glucose thresholds)
- Cleveland Clinic: Complete blood count (normal values for adults)
- Kim SH, Park MJ. Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab 2017. PMID 29025199
- Gajda PM, et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug Test Anal 2019. PMID 30136411
- Krug O, et al. Identification of black market products and potential doping agents in Germany 2010-2013. Eur J Clin Pharmacol 2014. PMID 25168622
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol 2026. PMID 42395176
- FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (ipamorelin acetate)
- German Sport University Cologne (WADA-accredited lab): S2 Peptide hormones, growth factors, related substances and mimetics (2026 Prohibited List)
Educational content, not medical advice. Reference ranges differ by lab, so read your results against the range printed on your own report, and have a clinician review anything out of range.